GYPA

Across TCGA pan-cancer cohorts, GYPA Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GYPA data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GYPA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GYPA expression acts as an unfavorable survival marker.

LIHC, OV, and LGG are the cancer types where GYPA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.079	0.774	<.001	24	view →
OV	OS	Median	II,III,IV	0.261	0.843	<.001	18	view →
LGG	OS	Median	All	0.317	0.811	.011	6	view →
SCLC	OS	Median	II,III,IV	0.301	0.706	.020	6	view →
SKCM	OS	Median	II,III,IV	0.245	0.731	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GYPA–LIHC (OS)

Open the LIHC breakdown →